---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013413"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:23:27.389093+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy

## Summary
- First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.
- Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.
- CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity.

## SEC filing metadata
- accession: 0001437749-25-013413
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/0001437749-25-013413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925013413/apyx20250428_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013413
- JSON: https://secwatch.observer/filing/0001437749-25-013413.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.